The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

When it comes to losing fat without extreme exercise, only a few medicines are worth considering. With the innovation in the medical world, physicians are now recommending the Ozempic weight loss ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

“This approval enables access to the approved Mounjaro pen in a more convenient ... it will compete with Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide), which launched in limited quantities ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Liraglutide was the medication evaluated in six trials, with exenatide, semaglutide and tirzepatide assessed in one trial each. Participants receiving a GLP-1 drug had a mean 8.1 kg body weight ...

GLP-1 injections, such as semaglutide and tirzepatide products like Ozempic, Wegovy, Mounjaro and Zepbound have led many consumers to spend significantly less money on food — both at grocery stores ...

Currently, approximately 2% of Americans are prescribed semaglutide, a GLP-1 agonist, underscoring its widespread adoption. Beyond weight loss and diabetes management, emerging research highlights ...

Ozempic, Mounjaro, and other glucagon-like peptide-1 medications, otherwise known as GLP-1s, are changing how Americans shop for groceries. In early January, Food & Wine published a story about ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i ... Cardiovascular outcomes with semaglutide by severity of chronic ...